Hua Medicine (Shanghai) Ltd. (2552.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Headquarters: CN
CEO: Li Chen
Listed since: Sep 14, 2018
Employees: 328

Market position

Day range

Current HK$2.56

HK$2.505HK$2.655

52-week range

Current HK$2.56

HK$1.97HK$4.95

Open: HK$2.60
Previous close: HK$2.60
Volume: 2.37M; 0.84× average
Average volume: 2.81M; Average daily volume
Market cap: 2.55B HKD
Beta: 0.8; Market reference 1
50-day average: HK$2.4353; +5.12% above average
200-day average: HK$3.0114; -14.99% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.94B CNY
P/E (TTM): -21.52×
P/B (TTM): 2.21×
P/S (TTM): 3.39×
EV / EBITDA: -17.74×
Earnings yield: 39.43%
Free cash flow yield: -2.18%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 60.64%
Operating margin: -16.23%
Net margin: -16.46%
Return on equity: 107.04%
Return on assets: 73.30%
Return on invested capital: -10.78%

Financial health

Debt / equity: 0.36×
Current ratio: 6.17×
Altman Z-score: 3.24
Piotroski F-score: 5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

480.18M CNY+87.65%

Operating income

−141.13M CNY+59.98%

Net income

1.08B CNY+1.33B CNY

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	480.18M CNY	255.89M CNY	76.61M CNY	17.6M CNY	—
Cost of goods sold	207.08M CNY	131.17M CNY	39.24M CNY	9.91M CNY	38.48M CNY
Gross profit	273.1M CNY	124.72M CNY	37.37M CNY	7.69M CNY	−38.48M CNY
Research and development	141.56M CNY	215.09M CNY	171.54M CNY	129.53M CNY	186.84M CNY
Selling, general, and administrative	279.92M CNY	269.94M CNY	203.9M CNY	145.28M CNY	134.84M CNY
Operating expenses	414.23M CNY	477.37M CNY	375.44M CNY	274.81M CNY	321.67M CNY
Interest income	11.19M CNY	13.44M CNY	16.51M CNY	4.24M CNY	5.04M CNY
Interest expense	7.94M CNY	8.61M CNY	7.91M CNY	3.67M CNY	3.95M CNY
Depreciation and amortization	31.63M CNY	14.94M CNY	36.24M CNY	31.78M CNY	11.98M CNY
Operating income	−141.13M CNY	−352.64M CNY	−289.09M CNY	−267.12M CNY	−320.52M CNY
Net income	1.08B CNY	−250.14M CNY	−211.23M CNY	−203.77M CNY	−330.95M CNY